Conventional Vaccine and Intradermal Vaccine Among HIV-infected Young Subjects

Safety and Immunogenicity of Influenza Vaccine Among HIV-infected Young Subjects: Conventional Vaccine Versus Intradermal Vaccine

Several studies have shown poor immune response to conventional influenza vaccines in HIV-infected individuals. This study was conducted expecting the more potent immunogenicity of intradermal vaccine compared with conventional intramuscular vaccine in HIV-infected adults.

During the 2011/2012 pre-influenza season, three vaccines were used in HIV-infected adults (18 to 60 years): inactivated intramuscular vaccine (Agripal), reduced-content intradermal vaccine (IDflu9μg) and standard-content intradermal vaccine (IDflu15μg). Serum hemagglutination-inhibiting (HI) antibodies and INF-γ ELISpot assay were measured at the time of vaccination and 1 month after vaccination. Adverse events were recorded for 7 days.

Inclusion Criteria:

• HIV-infected individuals who were not immunized with 2011/2012 influenza vaccine

Exclusion Criteria:

• known allergy to egg
• presentation of any febrile illness ≥37.5°C on the day of vaccination
• any history of hypersensitivity reaction to previous influenza vaccination
• any other vaccinations within the past one month
• use of immunosuppressive agent
• recipient of blood product or immunoglobulins during the previous three months
• any other conditions that might interfere with the study results